Cabaletta Bio, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Convertible Preferred Stock (Tables)

Convertible Preferred Stock (Tables)

12 Months Ended

Dec. 31, 2019

Partners Capital [Abstract]

Summary of Convertible Preferred Stock

. The following table summarizes the Company’s Convertible Preferred Stock:

		Series A Preferred								Series A-1 Preferred								Series A-2 Preferred								Series B Preferred								Total Convertible Preferred Stock
		Shares				Amount				Shares				Amount				Shares				Amount				Shares				Amount				Shares				Amount
Balance—December 31, 2017			—			$	—				—			$	—				—			$	—				—			$	—				—			$	—
Issuance on conversion of convertible notes			—				—				2,819,267				9,558				1,873,777				6,352				—				—				4,693,044				15,910
Issuance on milestone closing of convertible notes			—				—				4,553,452				15,436				—				—				—				—				4,553,452				15,436
Issuance			3,146,551				12,744				—				—				—				—				—				—				3,146,551				12,744
Issuance costs			—				(169	)			—				—				—				—												—				(169	)
Balance—December 31, 2018			3,146,551				12,575				7,372,719				24,994				1,873,777				6,352				—				—				12,393,047				43,921
Issuance			—				—				—				—				—				—				6,963,788				50,000				6,963,788				50,000
Exchange, including deemed dividend			—				—				—				—				(1,405,332	)			(4,764	)			1,405,332				10,090				—				5,326
Issuance costs			—				—				—				—				—				—				—				(1,293	)			—				(1,293	)
Conversion to common stock			(3,146,551	)			(12,575	)			(7,372,719	)			(24,994	)			(468,445	)			(1,588	)			(8,369,120	)			(58,797	)			(19,356,835	)			(97,954	)
Balance—December 31, 2019			—			$	—				—			$	—				—			$	—				—			$	—				—			$	—